<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01198613</url>
  </required_header>
  <id_info>
    <org_study_id>TR002</org_study_id>
    <nct_id>NCT01198613</nct_id>
  </id_info>
  <brief_title>ToleroMune Ragweed Exposure Chamber Study</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled Study to Evaluate Two Doses of ToleroMune Ragweed in Ragweed Allergic Subjects Following Challenge With Ragweed Allergen in an Environmental Exposure Chamber</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adiga Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cetero Research, San Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is believe that ragweed is the primary cause of autumn allergies and 87% of patients with
      ragweed allergy suffer rhinoconjunctivitis. ToleroMune Ragweed is a novel, synthetic,
      allergen-derived peptide desensitising vaccine, currently being developed for the treatment
      of ragweed allergy.

      This study will look at the efficacy, safety and tolerability of two doses of ToleroMune
      Ragweed in ragweed allergic subjects following challenge with ragweed in an EEC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a randomised, double-blind, placebo-controlled, parallel group
      study to evaluate the safety and tolerability of ToleroMune Ragweed in ragweed allergic
      subjects with allergic rhinoconjunctivitis,subjects may also have controlled asthma. The
      efficacy of ToleroMune Ragweed will be explored in subjects using an(Environmental Exposure
      Chamber)EEC.

      The study will consist of 3 study periods. In Period 1, Screening will be performed up to a
      maximum of 12 weeks before randomisation and may consist of one or two visits to the clinic,
      at the Investigator's discretion. Baseline Challenge will consist of 4 visits to the EEC at
      least 3 days before randomisation.

      In Period 2, subjects in each cohort complying with the inclusion/exclusion criteria will be
      randomised to one of five groups and will receive treatment every 2 weeks (Â±2 days) for 14
      weeks.

      In Period 3, Post Treatment Challenge will consist of 4 visits to the EEC 18-22 weeks after
      the first administration in the treatment period and assessments will be performed identical
      to those at the baseline challenge. Follow-up will be conducted 3-10 days after PTC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Rhinoconjunctivitis Symptom Score</measure>
    <time_frame>Upto 22 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom scores for ocular and nasal symptoms</measure>
    <time_frame>Upto 22 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acoustic Rhinometry</measure>
    <time_frame>Upto 22 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin prick testing</measure>
    <time_frame>Baseline and final follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ragweed specific IgE</measure>
    <time_frame>At baseline and at follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ragweed specific IgA</measure>
    <time_frame>At baseline and follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ragweed specific IgG4</measure>
    <time_frame>At baseline and at follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Upto 23 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">275</enrollment>
  <condition>Ragweed Allergy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ToleroMune Ragweed Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ToleroMune Ragweed Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ToleroMune Ragweed Regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ToleroMune Ragweed Regimen 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ToleroMune Ragweed</intervention_name>
    <description>Intradermal injection 1 x8 administrations 2 weeks apart</description>
    <arm_group_label>ToleroMune Ragweed Regimen 1</arm_group_label>
    <arm_group_label>ToleroMune Ragweed Regimen 2</arm_group_label>
    <arm_group_label>ToleroMune Ragweed Regimen 3</arm_group_label>
    <arm_group_label>ToleroMune Ragweed Regimen 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intradermal injection, 1x8 administrations 2 weeks apart</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Male or female, aged 18-65 years.

          -  Minimum 2-year documented history of rhinoconjunctivitis on exposure to ragweed.
             [Subjects may also have controlled asthma

          -  Positive skin prick test to ragweed allergen.

          -  Minimum qualifying rhinoconjunctivitis symptom scores

        Exclusion criteria

          -  History of asthma.

          -  A history of anaphylaxis to ragweed allergen.

          -  Subjects with an FEV1 &lt;70% of predicted.

          -  Subjects who cannot tolerate baseline challenge in the EEC.

          -  Subjects for whom administration of epinephrine is contra-indicated (e.g. subjects
             with acute or chronic symptomatic coronary heart disease or severe hypertension).

          -  A history of severe drug allergy, severe angioedema or anaphylactic reaction to food.

          -  A history of any significant disease or disorder (e.g. cardiovascular, pulmonary,
             gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic,
             neoplastic/malignant, psychiatric, major physical impairment).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepen Patel, MD, CCFP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cetero Research, San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>ON N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4W 1N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2010</study_first_submitted>
  <study_first_submitted_qc>September 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2010</study_first_posted>
  <last_update_submitted>October 6, 2011</last_update_submitted>
  <last_update_submitted_qc>October 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ragweed allergy</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <keyword>Exposure chamber</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>ToleroMune Ragweed</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

